Molecule News and Research

RSS

Computer simulation for predicting effectiveness of combination therapies for colon tumors

Scientist at Charité - Universitätsmedizin Berlin have used a computer simulation for predicting the effectiveness of various combination therapies for colon tumors. The study has been published in the current issue of the professional journal Molecular Systems Biology*.

28 Jun 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Karo Bio AB announced today the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.

26 Jun 2013

Caspase-2 protein contributes to cognitive decline associated with Alzheimer's disease

Researchers at Columbia University Medical Center have demonstrated that a protein called caspase-2 is a key regulator of a signaling pathway that leads to cognitive decline in Alzheimer's disease.

26 Jun 2013

Researchers find RNA molecule that interferes with lipoprotein production, reduces hyperlipidemia

Hyperlipidemia, a condition with high levels of fats circulating in the bloodstream, is a known risk factor for various cardiovascular and metabolic disorders. While the Western diet often contributes to high levels of lipids such as cholesterol and triglycerides, over-production of the body's own lipoproteins can lead to hyperlipidemia, independent of food intake.

25 Jun 2013

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.

25 Jun 2013

Th17 lymphocyte: The master coordinator of cellular inflammation in vessel wall

Every year, more than 16,000 Americans die as a result of what's known as an "aortic dissection" - a catastrophic rupture of the aorta, the body's largest artery. Once thought to be a simple structural failure, aortic dissection is now understood to be caused by an inflammatory process that weakens the artery's walls.

21 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

An advanced tumor is a complex ecosystem. Though derived from a single cell, it evolves as it grows until it contains several subspecies of cells that vary dramatically in their genetic traits and behaviors.

21 Jun 2013

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research.

21 Jun 2013

TSRI scientists find dual inhibitor that attacks two enzymes associated with Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have found a compound that could counter Parkinson's disease in two ways at once.

21 Jun 2013

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.

20 Jun 2013

Research shows interaction of tau and amyloid-beta in brain may increase progression of AD

For years, Alzheimer's researchers have focused on two proteins that accumulate in the brains of people with Alzheimer's and may contribute to the disease: plaques made up of the protein amyloid-beta, and tangles of another protein, called tau.

20 Jun 2013

Diapocynin antioxidant protects neurobehavioral function in mice with Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Research: Fetal exposure to BPA causes inflammation in fat tissues after birth

New research suggests that fetal exposure to the common environmental chemical bisphenol A, or BPA, causes increased inflammation in fat tissues after birth, which can lead to obesity and metabolic syndrome. Results of the animal study were presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

19 Jun 2013

New chemical probe confirms that hydrogen sulfide is generated by body's growing cells.

A new study confirms directly what scientists previously knew only indirectly: The poisonous "rotten egg" gas hydrogen sulfide is generated by our body's growing cells.

19 Jun 2013

Scientist discovers a way to reduce human cholesterol levels

Senior Brandeis research scientist Daniel Perlman has discovered a way to make phytosterol molecules from plants dispersible in beverages and foods that are consumed by humans, potentially opening the way to dramatic reductions in human cholesterol levels.

19 Jun 2013

New blood test finds cancer-related microRNA in blood before tumor development

A new blood test developed in the Gastrointestinal Cancer Research Lab at Baylor Research Institute is showing very promising results for finding cancer-related microRNA in the blood before a tumor develops in the colon.

19 Jun 2013

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point.

19 Jun 2013

Molecule News and Research

Computer simulation for predicting effectiveness of combination therapies for colon tumors

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Caspase-2 protein contributes to cognitive decline associated with Alzheimer's disease

Researchers find RNA molecule that interferes with lipoprotein production, reduces hyperlipidemia

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

Th17 lymphocyte: The master coordinator of cellular inflammation in vessel wall

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

TSRI scientists find dual inhibitor that attacks two enzymes associated with Parkinson's disease

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

Research shows interaction of tau and amyloid-beta in brain may increase progression of AD

Diapocynin antioxidant protects neurobehavioral function in mice with Parkinson's disease

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Research: Fetal exposure to BPA causes inflammation in fat tissues after birth

New chemical probe confirms that hydrogen sulfide is generated by body's growing cells.

Scientist discovers a way to reduce human cholesterol levels

New blood test finds cancer-related microRNA in blood before tumor development

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News